Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for ...

ARK Investment Management LLC lifted its position in Absci by 15.1% during the 3rd quarter. ARK Investment Management LLC now owns 6,337,622 shares of the company’s stock valued at $24,210,000 ...

Zachariah Branch should quickly emerge as one of the most impactful players on Georgia's football team, showcasing a combination of elite skills that make him a nightmare for opposing defenses ...

Equities analysts expect that Absci will post -0.9 earnings per share for the current fiscal year. Several institutional investors have recently added to or reduced their stakes in ABSI. FMR LLC ...

Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design ...

Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class ...

Absci Corporation and Owkin have announced a partnership to combine their advanced AI platforms for the rapid discovery and design of novel therapeutics. Absci, known for its generative AI in drug ...

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to ...

(MENAFN- GlobeNewsWire - Nasdaq) Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and ...

Absci (ABSI) and Owkin announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. Through this strategic partnership, Absci ...